$33.38-0.33 (-0.98%)
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Alkermes plc in the Healthcare sector is trading at $33.38. The stock is currently 8% below its 52-week high of $36.48, remaining 10.6% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why ALKS maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The ...
PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The consensus price target hints at a 29.1% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Alkermes recently highlighted new data from its Vibrance-1 phase 2 study of alixorexton in narcolepsy type 1, showing clinically meaningful improvements in wakefulness, cognition and fatigue over 13 weeks with a favorable safety profile, alongside growing evidence for LYBALVI’s impact on negative symptoms in schizophrenia. The combination of advancing an orexin 2 receptor agonist with Breakthrough Therapy designation and publishing longer-term LYBALVI outcomes may influence how investors...